Effect of KIOM-79 on diabetes-induced myocardial fibrosis in Zucker diabetic fatty rats

Evidence-based Complementary and Alternative Medicine

Volumn 2013, Issue , 2013, Pages

  Kim, Junghyun ^a   Sohn, Eunjin ^a   Kim, Chan Sik ^a   Lee, Yun Mi ^a   Jo, Kyuhyung ^a   Kim, Jin Sook ^a  

^a Korea Institute of Oriental Medicine (KIOM)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ANTIFIBROTIC AGENT; COLLAGEN TYPE 4; FIBRONECTIN; GLUCOSE; HERBACEOUS AGENT; KIOM 79; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; UROTENSIN II; UROTENSIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENE OVEREXPRESSION; GLUCOSE BLOOD LEVEL; HEART; HEART MUSCLE; HEART MUSCLE FIBROSIS; IMMUNOHISTOCHEMISTRY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TREATMENT DURATION; UPREGULATION; ZUCKER DIABETIC FATTY RAT;

EID: 84890073717     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2013/547653     Document Type: Article

References (35)

1. Candido R., Forbes J. M., Thomas M. C., Thallas V., Dean R. G., Burns W. C., Tikellis C., Ritchie R. H., Twigg S. M., Cooper M. E., Burrell L. M., A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circulation Research 2003 92 7 785 792 2-s2.0-0037453647 10.1161/01.RES.0000065620.39919.20 (Pubitemid 36457644)
2. Brownlee M., The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005 54 6 1615 1625 2-s2.0-20044376702 10.2337/diabetes.54. 6.1615 (Pubitemid 40770750)
3. Aragno M., Mastrocola R., Alloatti G., Vercellinatto I., Bardini P., Geuna S., Catalano M. G., Danni O., Boccuzzi G., Oxidative stress triggers cardiac fibrosis in the heart of diabetic rats. Endocrinology 2008 149 1 380 388 2-s2.0-37549058838 10.1210/en.2007-0877
4. Aronson D., Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. Journal of Hypertension 2003 21 1 3 12 2-s2.0-0037251741 10.1097/00004872-200301000-00002 (Pubitemid 36143498)
5. Mason R. M., Wahab N. A., Extracellular matrix metabolism in diabetic nephropathy. Journal of the American Society of Nephrology 2003 14 5 1358 1373 2-s2.0-0037407520 10.1097/01.ASN.0000065640.77499.D7 (Pubitemid 36519197)
6. Westermann D., Rutschow S., Jäger S., Linderer A., Anker S., Riad A., Unger T., Schultheiss H.-P., Pauschinger M., Tschöpe C., Contributions of inflammation and cardiac matrix metalloproteinase activity to cardiac failure in diabetic cardiomyopathy: the role of angiotensin type 1 receptor antagonism. Diabetes 2007 56 3 641 646 2-s2.0-33847342561 10.2337/db06-1163 (Pubitemid 46348458)
7. Way K. J., Isshiki K., Suzuma K., Yokota T., Zvagelsky D., Schoen F. J., Sandusky G. E., Pechous P. A., Vlahos C. J., Wakasaki H., King G. L., Expression of connective tissue growth factor is increased in injured myocardium associated with protein kinase C β 2 activation and diabetes. Diabetes 2002 51 9 2709 2718 2-s2.0-0036724631 (Pubitemid 34970923)
8. Tzanidis A., Hannan R. D., Thomas W. G., Onan D., Autelitano D. J., See F., Kelly D. J., Gilbert R. E., Krum H., Direct actions of Urotensin II on the heart: implications for cardiac fibrosis and hypertrophy. Circulation Research 2003 93 3 246 253 2-s2.0-0042525995 10.1161/01.RES.0000084382.64418.BC (Pubitemid 36993236)
9. Ames R. S., Sarau H. M., Chambers J. K., Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 1999 401 6750 282 286
10. Tian L., Li C., Qi J., Fu P., Yu X., Li X., Cai L., Diabetes-induced upregulation of urotensin II and its receptor plays an important role in TGF- β 1-mediated renal fibrosis and dysfunction. American Journal of Physiology-Endocrinology and Metabolism 2008 295 5 E1234 E1242 2-s2.0-57049159229 10.1152/ajpendo.90672.2008
11. Langham R. G., Kelly D. J., Gow R. M., Zhang Y., Dowling J. K., Thomson N. M., Gilbert R. E., Increased expression of urotensin II and urotensin II receptor in human diabetic nephropathy. American Journal of Kidney Diseases 2004 44 5 826 831 2-s2.0-7444244979 10.1053/j.ajkd.2004.07.021 (Pubitemid 39445914)
12. Dai H.-Y., Guo X.-G., Ge Z.-M., Li Z.-H., Yu X.-J., Tang M.-X., Zhang Y., Elevated expression of urotensin II and its receptor in diabetic cardiomyopathy. Journal of Diabetes and its Complications 2008 22 2 137 143 2-s2.0-39049141682 10.1016/j.jdiacomp.2006.10.008 (Pubitemid 351233049)
13. Li W. L., Zheng H. C., Bukuru J., De Kimpe N., Natural medicines used in the traditional Chinese medical system for therapy of diabetes mellitus. Journal of Ethnopharmacology 2004 92 1 1 21 2-s2.0-1942424088 10.1016/j.jep.2003.12.031 (Pubitemid 38510258)
14. Hur J., Donguibogam Paralled Version 1999 Seoul, Korea Committee of Dongui Bogam Translation, Bupin publishing Co.
15. Wong K. H., Li G. Q., Li K. M., Razmovski-Naumovski V., Chan K., Kudzu root: traditional uses and potential medicinal benefits in diabetes and cardiovascular diseases. Journal of Ethnopharmacology 2011 134 3 584 607 2-s2.0-79954422522 10.1016/j.jep.2011.02.001
16. Chiang C.-K., Sheu M.-L., Lin Y.-W., Wu C.-T., Yang C.-C., Chen M.-W., Hung K.-Y., Wu K.-D., Liu S.-H., Honokiol ameliorates renal fibrosis by inhibiting extracellular matrix and pro-inflammatory factors in vivo and in vitro. British Journal of Pharmacology 2011 163 3 586 597 2-s2.0-79955888192 10.1111/j.1476-5381.2011.01242.x
17. Tu C. T., Li J., Wang F. P., Li L., Wang J. Y., Jiang W., Glycyrrhizin regulates CD4+ T cell response during liver fibrogenesis via JNK, ERK and PI3K/AKT pathway. International Immunopharmacology 2012 14 4 410 421
18. Alarcon-Aguilara F. J., Roman-Ramos R., Perez-Gutierrez S., Aguilar-Contreras A., Contreras-Weber C. C., Flores-Saenz J. L., Study of the anti-hyperglycemic effect of plants used as antidiabetics. Journal of Ethnopharmacology 1998 61 2 101 110 2-s2.0-0032102928 10.1016/S0378-8741(98) 00020-8 (Pubitemid 28297899)
19. Kim J., Kim C. S., Sohn E., Lee Y. M., Jo K., Kim J. S., KIOM-79 protects AGE-induced retinal pericyte apoptosis via inhibition of NF-kappaB activation in vitro and in vivo. PLoS One 2012 7 8, article e43591
20. Ah Kang K., Kim J. S., Zhang R., Piao M. J., Ko D. O., Wang Z. H., Maeng Y. H., Eun S. Y., Hyun J. W., Induction of heme oxygenase-1 by plant extract KIOM-79 via Akt pathway and NF-E2 related factor 2 in pancreatic β -cells. Journal of Toxicology and Environmental Health A 2008 71 20 1392 1399 2-s2.0-49649117470 10.1080/15287390802271624
21. Kang K. A., Lee K. H., Kim S. Y., Kim H. S., Kim J. S., Hyun J. W., Cytoprotective effects of KIOM-79 on streptozotocin induced cell damage by inhibiting ERK and AP-1. Biological and Pharmaceutical Bulletin 2007 30 5 852 858 2-s2.0-34248140585 10.1248/bpb.30.852 (Pubitemid 46708625)
22. Kim Y. S., Jung D. H., Kim N. H., Lee Y. M., Jang D. S., Song G.-Y., Kim J. S., KIOM-79 inhibits high glucose or AGEs-induced VEGF expression in human retinal pigment epithelial cells. Journal of Ethnopharmacology 2007 112 1 166 172 2-s2.0-34247866186 10.1016/j.jep.2007.02.017 (Pubitemid 46702431)
23. Sohn E. J., Kim Y. S., Kim C.-S., Lee Y. M., Kim J. S., KIOM-79 prevents apoptotic cell death and AGEs accumulation in retinas of diabetic db/db mice. Journal of Ethnopharmacology 2009 121 1 171 174 2-s2.0-58049123856 10.1016/j.jep.2008.09.036
24. Jung D. H., Kim Y. S., Kim J. S., KIOM-79 prevents S100b-induced TGF- β 1 and fibronectin expression in mouse mesangial cells. Journal of Ethnopharmacology 2009 125 3 374 379 2-s2.0-69949100561 10.1016/j.jep.2009.08. 002
25. Kim J. S., Kim Y. S., Kim J., Kim C.-S., Sohn E. J., Lee Y. M., Jeong I.-H., Kim H., Jang D. S., KIOM-79, an inhibitor of AGEs-protein cross-linking, prevents progression of nephropathy in Zucker diabetic fatty rats. Evidence-Based Complementary and Alternative Medicine 2011 2011 10 2-s2.0-80052672697 10.1093/ecam/nep078 761859
26. Kim C.-S., Sohn E. J., Kim Y. S., Jung D. H., Jang D. S., Lee Y. M., Kim D.-H., Kim J. S., Effects of KIOM-79 on hyperglycemia and diabetic nephropathy in type 2 diabetic Goto-Kakizaki rats. Journal of Ethnopharmacology 2007 111 2 240 247 2-s2.0-34047179602 10.1016/j.jep.2006.11.023 (Pubitemid 46528078)
27. Huang J. S., Guh J. Y., Chen H. C., Hung W. C., Lai Y. H., Chuang L. Y., Role of receptor for advanced glycation end-product (RAGE) and the JAK/STAT-signaling pathway in AGE-induced collagen production in NRK-49F cells. Journal of Cellular Biochemistry 2001 81 1 102 113
28. Lee C.-I., Guh J.-Y., Chen H.-C., Lin K.-H., Yang Y.-L., Hung W.-C., Lai Y.-H., Chuang L.-Y., Leptin and connective tissue growth factor in advanced glycation end-product-induced effects in NRK-49F cells. Journal of Cellular Biochemistry 2004 93 5 940 950 2-s2.0-26444509640 10.1002/jcb.20222 (Pubitemid 44268945)
29. Zhou G., Li C., Cai L., Advanced glycation end-products induce connective tissue growth factor-mediated renal fibrosis predominantly through transforming growth factor β -independent pathway. American Journal of Pathology 2004 165 6 2033 2043 2-s2.0-9644284528 (Pubitemid 39578381)
30. Yan S. F., Ramasamy R., Naka Y., Schmidt A. M., Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circulation Research 2003 93 12 1159 1169 2-s2.0-0347381138 10.1161/01.RES.0000103862.26506.3D (Pubitemid 37543056)
31. Forbes J. M., Thallas V., Thomas M. C., Founds H. W., Burns W. C., Jerums G., Cooper M. E., The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. The FASEB Journal 2003 17 12 1762 1764 2-s2.0-0141483457
32. Douglas S. A., Tayara L., Ohlstein E. H., Halawa N., Giaid A., Congestive heart failure and expression of myocardial urotensin II. The Lancet 2002 359 9322 1990 1997 2-s2.0-0037042532 10.1016/S0140-6736(02)08831-1 (Pubitemid 34663713)
33. Totsune K., Takahashi K., Arihara Z., Sone M., Murakami O., Ito S., Kikuya M., Ohkubo T., Hashimoto J., Imai Y., Elevated plasma levels of immunoreactive urotensin II and its increased urinary excretion in patients with Type 2 diabetes mellitus: association with progress of diabetic nephropathy. Peptides 2004 25 10 1809 1814 2-s2.0-5144231012 10.1016/j.peptides.2004.06.024 (Pubitemid 39346225)
34. Sidharta P. N., Wagner F. D., Bohnemeier H., Jungnik A., Halabi A., Krähenbühl S., Chadha-Boreham H., Dingemanse J., Pharmacodynamics and pharmacokinetics of the urotensin II receptor antagonist palosuran in macroalbuminuric, diabetic patients. Clinical Pharmacology and Therapeutics 2006 80 3 246 256 2-s2.0-33748148272 10.1016/j.clpt.2006.05.013 (Pubitemid 44313907)
35. Zhang Y.-G., Li Y.-G., Liu B.-G., Wei R.-H., Wang D.-M., Tan X.-R., Bu D.-F., Pang Y.-Z., Tang C.-S., Urotensin II accelerates cardiac fibrosis and hypertrophy of rats induced by isoproterenol. Acta Pharmacologica Sinica 2007 28 1 36 43 2-s2.0-33845982537 10.1111/j.1745-7254.2006.00485.x (Pubitemid 46046624)